Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Switch Clinical Trial of Antiretrovirals to Compare the Impact of Doravirine Versus Integrase Inhibitors with Backbone of Emtricitabine and Tenofovir Alafenamide on Instigators of Atherosclerosis in Persons with Chronic Treated HIV.

Next Previous
Trial Profile

A Switch Clinical Trial of Antiretrovirals to Compare the Impact of Doravirine Versus Integrase Inhibitors with Backbone of Emtricitabine and Tenofovir Alafenamide on Instigators of Atherosclerosis in Persons with Chronic Treated HIV.

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doravirine (Primary) ; Emtricitabine; Tenofovir alafenamide
  • Indications HIV-1 infections
  • Focus Pharmacodynamics

Most Recent Events

  • 13 Mar 2025 Planned number of patients changed from 20 to 30.
  • 07 Mar 2024 Status changed from not yet recruiting to recruiting.
  • 29 Nov 2023 Planned initiation date changed from 1 Nov 2023 to 1 Feb 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top